Please login to the form below

Not currently logged in

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions


After making a profit of $6bn over two decades, Novartis is to sell its stake in fellow Swiss drugmaker Roche for more than $20bn.

Novartis has held the 53.3 million bearer shares in Roche – approximately one-third of the total – since it started acquiring a stake in the company in the early 2000s for a possible merger. The proposed merger, masterminded by ex-Novartis CEO Daniel Vasella, was vetoed by the Hoffman-La Roche family that controls Roche.

The price of $388.99 per share reflects the volume-weighted average price of Roche non-voting equity certificates (Genussschein) over the last 20 trading days.

The transaction makes no difference in the control of Roche as the ‘pool’ of shares controlled by the Hoffman-La Roche family means they hold a majority at Roche general meetings, although the voting power of the family pool will increase to just over two-thirds once the transaction is complete.

Roche says representatives of the family pool did not participate in the deliberations around the repurchase from Novartis. Roche’s board of directors has approved the repurchase, which will be debt-financed.

“I am convinced that the envisaged transaction is in the best interest of Roche and the holders of Roche equity securities from a strategic and economic perspective,” said the chair of its board, Christoph Franz. “As a result, Roche will be even better positioned strategically in the future to provide life-saving medicines and diagnostics to people around the world.”

Roche added that the deal, which came as a surprise to the company when Novartis approached them a few weeks ago, would mean ‘the disentanglement of the two competitors’ in order to ‘regain full strategic flexibility’.

Vas Narasimhan, CEO of Novartis, said: “After more than 20 years as a shareholder of Roche, we concluded that now is the right time to monetise our investment. Today’s announcement is consistent with our strategic focus and we intend to deploy the proceeds from the transaction in line with our capital allocation priorities to maximise shareholder value and continue to reimagine medicine.”

Analysts at financial consultants Jefferies said the deal was positive for both companies and would boost Roche’s earnings per share by 7% and help sustain profit growth next year, when COVID-19-related sales could decrease. For Novartis, the sale would simplify its structure and allow for other acquisitions.

Article by
Hugh Gosling

5th November 2021

From: Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...